Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab

Marischen, Lothar and Fritsch, Juergen and Ilic, Jovana and Wahl, Laura and Bertsch, Thomas and Knop, Stefan and Bold, Anna (2025) Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26 (3): 1262. ISSN 1661-6596, 1422-0067

Full text not available from this repository. (Request a copy)

Abstract

In treating cancer, immunotherapy has been established as a later-line treatment option in clinical practice. That includes stem cell transplantation, modified or activated immune cells, and antibodies directed against aberrant cells. As an unconventional immune cell subgroup, gamma delta T cells have been shown to provide effects against malignant cells. They exhibit an MHC-independent activation process, which could diminish graft-versus-host disease after an adoptive transfer of allogeneic cells. Over the last years, the efficacy of therapeutic antibodies has been improved. As a bi-specific antibody, mosunetuzumab binds to both CD3 and CD20, thereby providing close proximity between effector and target cells. Here, we set out to analyze the efficiency of gamma delta T cells' anti-tumor effects in combination with mosunetuzumab vs. the monoclonal anti-CD20 antibody obinutuzumab. Mosunetuzumab revealed improved responses of gamma delta T cells regarding their expression of IFN-gamma and CD107a and their cytotoxicity towards malignant B cells from lymphoma B cell lines. In comparison to obinutuzumab, mosunetuzumab led to an equivalent or enhanced cytotoxicity against B cell lymphoma cell lines and primary patient samples, where this effect was even more prominent. In summary, we consider the combination of stimulated gamma delta T cells and mosunetuzumab to be a promising therapeutic approach for future clinical trials.

Item Type: Article
Uncontrolled Keywords: CHRONIC LYMPHOCYTIC-LEUKEMIA; COMPLETE REMISSION; IN-VITRO; RITUXIMAB; EXPRESSION; THERAPY; GA101; CLL; INDUCTION; LYMPHOMA; immunotherapy; gamma delta T cells; bi-specific antibodies; mosunetuzumab
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Abteilung für Krankenhaushygiene und Infektiologie
Depositing User: Dr. Gernot Deinzer
Date Deposited: 17 Nov 2026 10:28
Last Modified: 17 Nov 2026 10:28
URI: https://pred.uni-regensburg.de/id/eprint/67060

Actions (login required)

View Item View Item